Andrew Ponte Net Worth

The estimated Net Worth of Andrew Joel Ponte is at least $98.5 mil dollars as of 31 March 2020. Mr. Ponte owns over 3,306 units of MYOS RENS Technology stock worth over $98,474 and over the last 5 years he sold MYOS stock worth over $0. In addition, he makes $0 as Independent Director at MYOS RENS Technology.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Ponte MYOS stock SEC Form 4 insiders trading

Andrew has made over 2 trades of the MYOS RENS Technology stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 3,306 units of MYOS stock worth $3,339 on 31 March 2020.

The largest trade he's ever made was buying 82,645 units of MYOS RENS Technology stock on 5 March 2020 worth over $100,000. On average, Andrew trades about 42,976 units every 13 days since 2020. As of 31 March 2020 he still owns at least 97,499 units of MYOS RENS Technology stock.

You can see the complete history of Mr. Ponte stock trades at the bottom of the page.

Andrew Ponte biography

Andrew Ponte serves as Independent Director of the Company. He has experience with multiple ownership platforms such as private equity, entrepreneur, public, hedge fund, and Chapter 11 reorganization and has been involved in various acquisitions and integrations. Mr. Ponte was previously Senior Vice President of the sales and business unit at Central Garden and Pet from May of 2015 to February of 2019. Prior to that, Mr. Ponte spent 15 years as an executive at United Pet Group (now Spectrum Brands) where he served a variety of positions from 1999 through 2015 including Vice President of Sales & Marketing, Vice President of Sales and Trade Marketing, Vice President of Sales and Walmart Team Leader. Prior to that, he held various sales and marketing management positions, initially with Dogloo, Inc. and Doskocil, Inc (after the merger of the two companies). Prior to that, he spent 8 years with Koch Industries in various leadership positions in sales, marketing, accounting and finance. Mr. Ponte holds a BA in Accounting from Kansas State University.

How old is Andrew Ponte?

Andrew Ponte is 56, he's been the Independent Director of MYOS RENS Technology since 2019. There are 5 older and 2 younger executives at MYOS RENS Technology. The oldest executive at MYOS RENS Technology, Inc. is Christopher Dewey, 75, who is the Independent Director.

What's Andrew Ponte's mailing address?

Andrew's mailing address filed with the SEC is C/O MYOS RENS TECHNOLOGY INC., 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS, NJ, 07927.

Insiders trading at MYOS RENS Technology

Over the last 12 years, insiders at MYOS RENS Technology have traded over $0 worth of MYOS RENS Technology stock and bought 2,115,845 units worth $2,654,259 . The most active insiders traders include David J Matlin, Christopher Pechock, eJoseph Mannello. On average, MYOS RENS Technology executives and independent directors trade stock every 78 days with the average trade being worth of $59,361. The most recent stock trade was executed by Joseph Mannello on 31 March 2020, trading 16,529 units of MYOS stock currently worth $16,694.

What does MYOS RENS Technology do?

MYOS RENS Technology, Inc. operates as a nutrition company, develops and markets products that improve muscle health and performance. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk, intended to increase lean muscle mass, size, and strength. The company was founded on April 11, 2007 and is headquartered in Cedar Knolls, NJ.

Complete history of Mr. Ponte stock trades at MYOS RENS Technology

MYOS RENS Technology executives and stock owners

MYOS RENS Technology executives and other stock owners filed with the SEC include:

• Joseph Mannello,
  Chief Executive Officer, Director
• Robert Hariri,
  Independent Chairman of the Board
• Eric Zaltas,
  Independent Director
• Andrew Ponte,
  Independent Director
• Christopher Pechock,
  Independent Director
• Victor Mandel,
  Independent Director
• Christopher Dewey,
  Independent Director
• Louis Aronne,
  Independent Director
• Ren Ren,
  Director
• Sapna Srivastava,
  Director
• Joseph Dos Santos,
  Chief Financial Officer
• Kenrick Bryce Toussaint,
  Chief Executive Officer
• Buzz Aldrin,
  Director
• Zhengguang Lyu,
  Director
• Robert C. Jr. Ashton,
  Chief Medical Officer
• Peter Diamandis,
  Director
• John Craig Venter,
  Director
• Peter Levy,
  COO & Executive VP
• John Nosta,
  Director
• Carl De Freitas,
  Interim CFO
• Glen R. Fleischer,
  Chief Executive Officer
• David J Matlin,
  10% owner